Returning to the Beurs van Berlage, Amsterdam for its sixth edition on Tuesday, 19th – Wednesday, 20th January 2027, Pharma & Biotech Patent Litigation Europe continues to place the priorities of the life science patent community at the heart of its programme.
The two-day event track unites 550+ attendees, including in-house IP counsel, private practice experts, judges and policymakers, and provides a dedicated forum for exploring the latest developments and most pressing strategic questions defining global life science patent litigation right now.
Through formats ranging from panel discussions, judicial interviews and focused roundtable conversations to quick-fire presentations and brand-new interactive workshops, the 2027 edition of Pharma & Biotech Patent Litigation Europe covers a comprehensive range of topics.
Topics Include
- Cross-border patent litigation and building strategies for parallel disputes across global jurisdictions
- Practical challenges and international trends in the enforcement of method of manufacturing claims
- Preliminary injunctions case law review and what litigators need to know for 2027
Co-ordinating decisions around whether to oppose, litigate or settle in modern patent disputes
- Biosimilars litigation and strategies for navigating exclusivity enforcement
- Innovator-innovator enforcement in the era of blockbuster therapies and next-generation technology
- EU and Hatch-Waxman trends in innovator-generic treatment-related secondary patent litigation
- Bolar and Exclusivity Reform in Europe under the EU Pharma Package and Biotech Act
Why Attend?
- Access perspectives from every corner of the life science ecosystem – with a 50% in-house counsel audience representing the full spectrum of innovator, biotech, generic, biosimilar and MedTech organisations, the event provides a rare opportunity to meet and exchange perspectives with industry peers across the sector.
Hear expert perspectives on the patent litigation issues that matter most – from treatment-related secondary patent litigation and process patent enforcement to SPCs, biosimilars and innovator-vs-innovator disputes, stay up-to-date as new decisions continue to shape life science IP and broader legal strategy.
- Receive multi-jurisdictional judicial insights from across the life sciences sector – hear directly from judges at the UPC and leading national courts as they discuss procedural developments, emerging trends and the practical considerations influencing outcomes in the pharmaceutical and biotechnology space.
- Benefit from strategic discussions that move beyond the case law – explore how leading in-house and external life science IP counsel are co-ordinating parallel disputes, managing dispute exposure and navigating the interplay between patent opposition, litigation and settlement.
- Gain a truly international perspective – with jurisdictions including the Netherlands, Germany, the UK, Poland, the USA, Canada, Brazil, India and China all represented on the programme, delegates will build an integrated, up-to-date view of the challenges and developments shaping global life science patent disputes.
- Meet all the key stakeholders shaping life sciences patent strategy in one place – the event unites senior in-house counsel who instruct law firms and allocate external legal spend with private practice litigators, judges, policymakers, regulators, consultants and solution providers from across the sector.